<DOC>
	<DOCNO>NCT00772902</DOCNO>
	<brief_summary>This study investigate whether human immunodeficiency virus type 1 ( HIV-1 ) infect subject raise cholesterol switch nucleoside reverse transcriptase inhibitor ( NRTI ) backbone Kivexa ( Epzicom ) Truvada improvement fast total cholesterol 12 week treatment . The study also investigate whether improvement beneficial effect overall cardiovascular risk .</brief_summary>
	<brief_title>ROCKET II - Randomized Open Label Switch Cholesterol Elevation Kivexa + Kaletra Evaluation Trial</brief_title>
	<detailed_description>This Phase 4 , open-label , randomize , multicenter ( European Union ) , control study ass effect lipid profile switch stable highly active antiretroviral therapy ( HAART ) regimen Kivexa + Kaletra Truvada + Kaletra adult HIV-1 infected subject raise cholesterol .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>≥ 18 year old Plasma HIV1 RNA &lt; 50 copies/mL screen ≥ 12 week prior Screening Stable HAART regimen Kivexa + Kaletra ≥ 24 week prior Screening Documented confirm raise total cholesterol ≥ 5.2 mmol/L ( ≥ 200 mg/dL ) last two consecutive test ( least 4 week apart ) Fasted total cholesterol ≥ 5.2 mmol/L ( ≥ 200 mg/dL ) Screening Subject willing continue current unmodified HAART 12 week randomize Group 2 Subjects require concomitant lipid regulate therapy must establish stable dose/frequency ≥ 12 week prior Screening expect remain stable dose frequency throughout treatment phase study . Simvastatin lovastatin allow . Adequate renal function calculate creatinine clearance ≥ 60 mL/min accord CockcroftGault formula Negative serum pregnancy test ( female childbearing potential i.e. , surgically sterile least 2 year postmenopausal ) Serum Total Bilirubin ≤ 1.5 mg/dL ( Note : In case clinically insignificant , asymptomatic elevate Serum Total Bilirubin [ e.g . due Gilbert Syndrome ] subject may enrol study Serum Total Bilirubin &gt; 1.5 mg/dL agreement Medical Monitor ) Women childbearing potential ( WOCBP ) must use highly effective method contraception avoid pregnancy throughout study 30 day last dose study drug manner risk pregnancy minimize Female subject postmenopausal less 2 year require follicle stimulate hormone ( FSH ) ≥ 40 mIU/mL . If FSH &lt; 40 mIU/mL , subject must agree use highly effective method birth control participate study . Male subject sexually active must willing use effective barrier contraception ( e.g . condom spermicide ) heterosexual intercourse screen completion study continue 30 day last dose study drug Life expectancy ≥ 1 year The ability understand sign write informed consent form , must obtain prior initiation study procedure . Pregnant lactate subject Previous treatment emtricitabine ( FTC ) , tenofovir DF ( TDF ) adefovir dipivoxil ( ADV ) Known hypersensitivity emtricitabine ( FTC ) , tenofovir DF ( TDF ) , Truvada excipients ( e.g. , lactose monohydrate ) Documented resistance study drug ( either genotypic phenotypic ) Severe hepatic impairment Hepatitis B infection viral load &gt; 1000 copies/mL Screening Hepatitis C infection require therapy Treatment interferon pegylated interferon within 18 month prior Screening Hepatic transaminase ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) ≥ 5 × upper limit normal ( ULN ) Subjects receive ongoing therapy medication contraindicate study drug . Administration medication must discontinue least 28 day prior Baseline visit duration study period . Active , serious infection ( HIV infection ) require parenteral antibiotic therapy within 15 day prior screen Prior history significant renal bone disease Any current know clinical symptomatic laboratory parameter Gilead Sciences , Inc. , Grade 4 . Asymptomatic Grade 4 abnormality permit discretion investigator deem clinically appropriate ( exclude adverse event laboratory parameter mention elsewhere inclusion/exclusion criterion ) . Abnormalities deem insignificant investigator must discuss Medical Monitor prior enrollment . Malignancy cutaneous Kaposi sarcoma ( KS ) basal cell carcinoma . Subjects biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study Current alcohol substance use judge investigator potentially interfere subject study compliance Subjects currently take part clinical trial use investigational product , exception study treatment study stop 1 month prior baseline Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>non-HDL cholesterol</keyword>
	<keyword>triglyceride</keyword>
	<keyword>cholesterol</keyword>
</DOC>